Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GPC1 scFv-Fc fusion protein
- Development stage
- Preclinical
- Lead developer
- Kyoto University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The anti-GPC1 scFv-Fc fusion protein is a recombinant diagnostic tool designed to detect the expression of glypican-1 (GPC1) in human cancers. Developed by a consortium of Japanese universities, the protein consists of a single-chain variable fragment (scFv) derived from the anti-GPC1 monoclonal antibody clone 1-12, fused to a mouse IgG2a Fc region. This construct is intended to serve as a companion diagnostic or research probe to identify patients suitable for GPC1-targeted CAR-T cell therapies, as the scFv format more closely mimics the binding interface of a CAR-T cell than a full-length antibody. Preclinical studies have demonstrated its ability to successfully detect GPC1 on the cell membrane of lung and esophageal carcinoma cell lines using flow cytometry, fluorescence microscopy, and immunohistochemistry.
- Other names
- anti-GPC1 scFv-mIgG2a_Fc fusion protein
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)GPC1 (Glypican-1)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on anti-GPC1 scFv-Fc fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GPC1 scFv-Fc fusion protein.